- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Reports of hepatosplenic T-cell lymphoma in patients taking tumor necrosis factor blockers, azathioprine, mercaptopurine continue
According to a new safety communication recently released by FDA, the agency is continuing to receive reports of a rare but aggressive white blood cell cancer often referred to as hepatosplenic T-cell lymphoma in patients receiving tumor necrosis factor blockers, azathioprine, and mercaptopurine.
Key Points
According to a new safety communication recently released by FDA, the agency is continuing to receive reports of a rare but aggressive white blood cell cancer often referred to as hepatosplenic T-cell lymphoma (HSTCL) in patients receiving tumor necrosis factor (TNF) blockers (including infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab), azathioprine, and mercaptopurine.
Prior to this safety communication, FDA reviewed data from the Adverse Event Reporting System (AERS) database, the medical literature, and the HSTCL Cancer Survivors' Network in order to identify cases of HSTCL associated with the use of TNF blockers, azathioprine, mercaptopurine, or their combination. From the first approval of a TNF blocker through the end of 2010, the agency identified a total of 43 cases of HSTCL linked to the use of these drugs.
Synthesis of the data suggested the majority of cases of HSTCL occurred in patients treated with a combination of these immunosuppressive agents; however, cases of HSTCL have been reported in patients receiving azathioprine or mercaptopurine alone. In regard to TNF blockers, infliximab, adalimumab, or the combination of the 2 were linked to the greatest number of cases (27 cases), although in many of these cases patients were also receiving azathioprine or mercaptopurine concomitantly. To date, no cases of HSTCL have been reported with the TNF blockers certolizumab or golimumab.
FDA previously warned the public of an increased risk of lymphoma with the use of TNF blockers. At that time, warnings were added to the prescribing information of these products.
The Agency noted product labels for infliximab and adalimumab have already been updated and the product labels for azathioprine and mercaptopurine will be updated to include warnings about HSTCL.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
